Posted: 16 July 2024 Alkira Bio uses its proprietary LASEREDD® technology platform to discover therapeutic antibodies directed against previously out of reach targets, pioneering new possibilities for drug discovery. The seed financing from Curie.Bio recognises Alkira Bio’s advanced…
Posted: 16 July 2024 Monash University researchers will develop a first of its kind inhaler device to conveniently treat respiratory viruses, while University of York researchers will screen 200 animal viruses to assess human pandemic risk and inform proactive…
Posted: 16 July 2024 The Allan Labor Government is ensuring Victoria’s medical research sector can continue to drive nation-leading infectious disease treatments and develop new products, grow exports and create jobs – with the opening of the Medicines Manufacturing…
Posted: 16 July 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase…
Posted: 11 July 2024 Victorian Deputy Premier and Minister for Medical Research the Hon Ben Carroll today officially opened the newly built Medicines Manufacturing Innovation Centre (MMIC) within the heart of the Monash Technology Precinct, Clayton. Funded through…
Posted: 9 July 2024 Closes: 22 July 2024 The Biotech Innovators Program is designed for Victorian based scientists, researchers, clinicians, SME’s and tech transfer professionals who are looking to build their research translation skills. Under the guidance of…
Posted: 9 July 2024 After an extensive global search, Professor Peter van Wijngaarden has been named as the next Director and CEO of The Florey Institute of Neuroscience and Mental Health. Board Chair Mr Martin Adams said Professor van Wijngaarden…
Posted: 4 July 2024 Peter Mac researchers have taken the first step towards designing rapid personalised cancer treatments by ‘cutting out’ disease-causing RNA. The findings, published in Nature Structural & Molecular Biology Journal, demonstrate how an innovative technology called…
Posted: 4 July 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that it has now recruited 26 patients in the Phase 2a stage of its clinical trial investigating narmafotinib in the treatment…
Posted: 4 July 2024 Businesses are increasingly making environmental sustainability claims when marketing their goods, services or investment products. Consumers are ever more conscious of environmental issues and are seeking to reduce the negative impact on the environment…
Posted: 4 July 2024 Companies involved in the supply of therapeutic goods in Australia must ensure that their advertising complies with the requirements of the Therapeutic Goods Act 1989 (Cth), the Therapeutic Goods Advertising Code (Advertising Code) and the Australian Consumer Law. The…
Posted: 2 July 2024 Australia’s national science agency, CSIRO, will partner with governments across the Pacific and Southeast Asia to help them better prepare for, and respond to, disease outbreaks. Emerging and endemic infectious diseases in humans and…